Ma D, Mellon J, Niederkorn J Y
Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas 75235, USA.
Invest Ophthalmol Vis Sci. 1998 Sep;39(10):1835-46.
To determine the optimal conditions for enhancing corneal allograft survival by oral immunization with donor-specific alloantigens.
CB6F1 mice were orally immunized with various doses of C3H/Hej corneal epithelial and endothelial cells before receiving orthotopic C3H/Hej corneal allografts. Paraformaldehyde-fixed corneal cells were compared with viable corneal cells for their capacity to promote corneal allograft survival. The mucosal adjuvant, cholera toxin B (CTB), was examined for its capacity to enhance corneal graft survival when given separately or conjugated to corneal cells used for oral immunization. Oral immunization was also evaluated for its capacity to prevent immunologic rejection in three high-risk settings: preimmunized hosts, hosts with prevascularized graft beds, and grafts that contain donor-specific Langerhans' cells.
Optimal graft survival occurred when 2 x 10(6) corneal cells were administered orally 10 days before orthotopic corneal transplantation. Paraformaldehyde-fixed corneal cells were as effective as viable cells in preventing corneal graft rejection. Cholera toxin B enhanced the efficacy of oral immunization when conjugated with the orally administered corneal cells but was ineffectual when administered separately. Oral immunization with donor corneal cells enhanced corneal graft survival in all three high-risk settings.
Oral immunization with donor cells is an effective strategy for enhancing corneal graft survival and preventing graft rejection in high-risk settings. Graft enhancement is optimized when the orally administered cells are conjugated with CTB and administered before corneal transplantation. Because fixed cells retain their capacity to enhance corneal graft survival, it may be possible to store donor cells for long-term use in high-risk hosts.
通过口服供体特异性同种异体抗原来确定提高角膜移植存活率的最佳条件。
在接受原位C3H/Hej角膜移植前,用不同剂量的C3H/Hej角膜上皮细胞和内皮细胞对CB6F1小鼠进行口服免疫。将多聚甲醛固定的角膜细胞与活角膜细胞促进角膜移植存活的能力进行比较。检测黏膜佐剂霍乱毒素B(CTB)单独给予或与用于口服免疫的角膜细胞偶联时提高角膜移植存活的能力。还评估了口服免疫在三种高风险情况下预防免疫排斥的能力:预先免疫的宿主、移植床有血管形成的宿主以及含有供体特异性朗格汉斯细胞的移植物。
在原位角膜移植前10天口服2×10⁶个角膜细胞时,移植存活率最佳。多聚甲醛固定的角膜细胞在预防角膜移植排斥方面与活细胞一样有效。霍乱毒素B与口服的角膜细胞偶联时可增强口服免疫的效果,但单独给予时无效。用供体角膜细胞进行口服免疫在所有三种高风险情况下均提高了角膜移植存活率。
用供体细胞进行口服免疫是提高角膜移植存活率和预防高风险情况下移植排斥的有效策略。当口服的细胞与CTB偶联并在角膜移植前给予时,移植增强效果最佳。由于固定细胞保留了其提高角膜移植存活的能力,因此有可能储存供体细胞供高风险宿主长期使用。